AFLAC Inc., Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend

COLUMBUS, Georgia - October 28, 2009 - Aflac Incorporated today reported its third quarter results.

Reflecting the benefit from a stronger yen/dollar exchange rate, total revenues rose 22.6% to $4.5 billion during the third quarter of 2009, compared with a year ago. Net earnings were $363 million, or $.77 per diluted share, compared with $100 million, or $.21 per share, a year ago.

Net earnings in the third quarter of 2009 included after-tax realized investment losses of $226 million, or $.48 per diluted share, compared with realized investment losses of $389 million, or $.81 per share in the third quarter of 2008. Of the realized investment losses in the third quarter of 2009, $212 million resulted from impairment losses on perpetual, or so-called "hybrid," securities of four issuers. The impairment loss on the perpetual securities was determined using the equity impairment method because their credit ratings are below investment grade. No impairment charges will be recorded on a statutory accounting basis for these perpetual securities because Aflac's credit analysis suggests that the issuers of the perpetual securities that were impaired on a GAAP basis will be able to meet their contractual obligations for payment. The company also realized investment losses of $22 million from the impairment of a collateralized debt obligation and $5 million primarily from the impairment of collateralized mortgage obligations. In addition, the company realized $13 million of investment gains from sales and redemptions of investment securities.

Aflac believes that an analysis of operating earnings, a non-GAAP financial measure, is vitally important to an understanding of the company's underlying profitability drivers. Aflac defines operating earnings as the profits derived from operations before realized investment gains and losses, the impact from ASC 815 (or hedging activities, formerly referred to as SFAS 133), and nonrecurring items. Management uses operating earnings to evaluate the financial performance of Aflac's insurance operations because realized gains and losses, the impact from ASC 815, and nonrecurring items tend to be driven by general economic conditions and events, and therefore may obscure the underlying fundamentals and trends in Aflac's insurance operations.

Furthermore, because a significant portion of Aflac's business is in Japan, where the functional currency is the Japanese yen, the company believes it is equally important to understand the impact on operating earnings from translating yen into dollars. Aflac Japan's yen-denominated income statement is translated from yen into dollars using an average exchange rate for the reporting period, and the balance sheet is translated using the exchange rate at the end of the period. However, except for a limited number of transactions, the company does not actually convert yen into dollars. As a result, Aflac views foreign currency as a financial reporting issue and not as an economic event for the company or its shareholders. Because changes in exchange rates distort the growth rates of operations, readers of Aflac's financial statements are also encouraged to evaluate financial performance excluding the impact of foreign currency translation. The chart toward the end of this release presents a comparison of selected income statement items with and without foreign currency changes to illustrate the effect of currency.

Operating earnings in the third quarter were $589 million, compared with $493 million in the third quarter of 2008. Operating earnings per diluted share rose 22.5% to $1.25, compared with $1.02 a year ago.

The stronger yen/dollar exchange rate increased operating earnings per diluted share by $.09 during the quarter. Excluding the impact from the stronger yen, operating earnings per share increased 13.7%.

Results for the first nine months of 2009 also benefited from the stronger yen. Total revenues rose 11.1% to $13.7 billion, compared with $12.3 billion a year ago. Net earnings were $1.2 billion, or $2.66 per diluted share, compared with $1.1 billion, or $2.19 per share, for the first nine months of 2008. Operating earnings for the first nine months of 2009 were $1.7 billion, or $3.67 per diluted share, compared with $1.5 billion, or $3.02 per share, in 2008. Excluding the benefit of $.23 per share from the stronger yen, operating earnings per diluted share rose 13.9% for the first nine months of 2009.

Total investments and cash at the end of September 2009 were $71.6 billion, compared with $65.6 billion at June 30, 2009. The increase in total investments and cash reflected a stronger yen at the end of the period and improvement in the fair values of the company's investments, compared with invested asset values at the end of the second quarter of 2009. Gross unrealized losses on investment securities classified as available for sale were $3.8 billion at September 30, 2009, compared with $4.9 billion at June 30, 2009.

Shareholders' equity was $7.9 billion at September 30, 2009, compared with $6.4 billion at June 30, 2009. Shareholders' equity at September 30, 2009, included a net unrealized loss on investment securities of $1.1 billion, compared with a net unrealized loss of $2.1 billion at the end of June 2009. Shareholders' equity per share was $16.85 at the end of the third quarter of 2009, compared with $13.58 per share at the end of the second quarter of 2009. The annualized return on average shareholders' equity in the third quarter was 20.4%. On an operating basis (excluding realized investment losses, the impact of ASC 815 on net earnings, and unrealized investment gains/losses in shareholders' equity), the annualized return on average shareholders' equity was 27.0% for the third quarter of 2009.

AFLAC JAPAN

In the third quarter, Aflac Japan's premium income in yen rose 3.4%, and net investment income declined 2.0%. Investment income growth in yen terms was suppressed by the stronger yen/dollar exchange rate because approximately 33% of Aflac Japan's third quarter investment income was dollar-denominated. Excluding the impact of the stronger yen, net investment income increased 2.9% in the quarter. Total revenues in yen were up 2.6%. Due to continued improvement in the benefit ratio, the pretax operating profit margin expanded from 18.3% to 20.0%. As a result, pretax operating earnings in yen increased 11.8%. For the first nine months, premium income in yen increased 3.4%, and net investment income was down .6%. Total revenues were up 2.8%, and pretax operating earnings grew 10.6%.

The average yen/dollar exchange rate in the third quarter of 2009 was 93.56, or 15.1% stronger than the average rate of 107.70 in the third quarter of 2008. For the first nine months, the average exchange rate was 94.79, or 11.6% stronger than the rate of 105.75 a year ago. Aflac Japan's growth rates in dollar terms for both the third quarter and first nine months of the year were magnified as a result of the stronger average yen/dollar exchange rates.

Reflecting the stronger yen, premium income in dollars rose 18.9% to $3.1 billion in the third quarter. Net investment income was up 12.7% to $568 million. Total revenues increased 18.0% to $3.6 billion. Pretax operating earnings advanced 28.7% to $725 million. For the first nine months of the year, premium income was $9.0 billion, or 15.4% higher than a year ago. Net investment income rose 10.9% to $1.7 billion. Total revenues were up 14.7% to $10.7 billion. Pretax operating earnings were $2.1 billion, or 23.4% higher than a year ago.

Aflac Japan's total new annualized premium sales increased 6.5% to ¥30.0 billion, or $320 million in the third quarter. For the first nine months of 2009, total new annualized premium sales were up 3.7% to ¥87.5 billion, or $922 million. The increase in third quarter sales reflected strong results in the medical and ordinary life insurance product categories. Although Aflac Japan's revised medical product was just introduced in late August, the initial response from consumers was very positive. As a result, medical sales rose 13.8% in the third quarter. The ordinary life category was again led by strong child endowment

sales. In addition, sales through the bank channel continued to improve. Bank channel sales in the third quarter rose 66.1%, compared with a year ago, to a record ¥2.2 billion.

AFLAC U.S.

Aflac U.S. premium income increased 3.0% to $1.1 billion, and net investment income was down 4.4% to $123 million. Total revenues rose 2.2% to $1.2 billion in the third quarter. Pretax operating earnings were $216 million, an increase of 5.7%. For the first nine months of the year, premium income rose 3.6% to $3.3 billion. Net investment income declined .4% to $375 million. Total revenues were up 3.2% to $3.7 billion, and pretax operating earnings rose 5.6% to $617 million.

Aflac U.S. total new annualized premium sales continued to reflect weak economic conditions in the United States. In the third quarter, total new sales declined 7.2% to $342 million. For the nine months, total new sales were $1.0 billion, or 6.4% lower than a year ago. However, growth in the number of new payroll accounts remained strong and encouraging. Newly established payroll accounts rose 15.0% in the third quarter and 11.5% for the first nine months of the year. New agent recruitment also remained solid. Newly recruited agents rose 9.4% during the third quarter to more than 7,000. For the first nine months, new agent recruitment was 16.4% higher than a year ago.

DIVIDEND

The board of directors declared the fourth quarter cash dividend. The fourth quarter dividend of $.28 per share is payable on December 1, 2009, to shareholders of record at the close of business on November 18, 2009.

OUTLOOK

Commenting on the company's third quarter results, Chairman and Chief Executive Officer Daniel P. Amos stated: "I continue to be encouraged by our financial and operating performance so far this year, especially in light of the weak economic conditions. Although net earnings continued to reflect larger-than-usual realized investment losses, the losses in the third quarter were significantly lower than a year ago. In addition, Aflac's operating earnings growth was again robust and consistent with our objective for the year. I am also very pleased that our overall capital position remained strong. Despite pressure from credit rating downgrades on some of our investments, we estimate that our risk-based capital ratio was 405% at the end of September, which exceeds our internal target.

"We remain cautious on the outlook for new sales in the United States due to ongoing economic weakness. It's clear that Aflac U.S. new annualized premium sales will fall short of our annual objective of flat to 5% growth this year. However, through new agent recruitment, effective training programs and new payroll account growth, we continue to believe we are positioning Aflac U.S. for a better sales year in 2010. In our largest market, we believe Aflac Japan will achieve its annual objective of flat sales to a 5% increase for the full year. With a tremendous consumer response to our recently introduced products and continued growth through the bank channel, we also believe we can extend Aflac Japan's sales momentum into 2010. Overall, we have great confidence in our business model and in the need for our products in Japan and the United States.

"We are also confident we will achieve our 2009 objective of a 13% to 15% increase in operating earnings per diluted share, excluding the impact of foreign currency. If the yen averages 90 to 95 to the dollar in the last three months of the year, we would expect reported operating earnings to be in the range of $1.08 to $1.16 per diluted share in the fourth quarter. Under that scenario, we would expect full-year operating earnings per diluted share to be in the range of $4.75 to $4.83. For 2010, our objective remains a 9% to 12% increase in operating earnings per diluted share before the impact of the yen/dollar exchange rate. Although we are keenly focused on achieving our 2009 and 2010 earnings targets, our primary objective is to maintain a strong balance sheet that our customers and owners can rely on in this challenging environment."

ABOUT AFLAC

For more than 50 years, Aflac products have given policyholders the opportunity to direct cash where it is needed most when a life-interrupting medical event causes financial challenges. As the number one provider of guaranteed-renewable insurance in the United States and the number one insurance company in terms of individual insurance policies in force in Japan, Aflac insurance products provide protection to more than 40 million people worldwide. Aflac has been recognized by Ethisphere magazine as one of the World's Most Ethical Companies for three consecutive years and was also named by the Reputation Institute as the Most Reputable Company in the Global Insurance Industry for two consecutive years. In 2009 Fortune magazine recognized Aflac as one of the 100 Best Companies to Work For in America for the eleventh consecutive year. Fortune magazine also ranked Aflac No. 1 on its global list of the Most Admired Companies in the Life and Health Insurance category. Aflac appears on Hispanic Enterprise magazine's list of the 50 Best Companies for Supplier Diversity and on Black Enterprise magazine's list of the 40 Best Companies for Diversity. Aflac was also named by Forbes magazine as America's Best-Managed Company in the Insurance category. Aflac Incorporated is a Fortune 500 company listed on the New York Stock Exchange under the symbol AFL. To find out more about Aflac, visit aflac.com.

A copy of Aflac's Financial Analysts Briefing (FAB) supplement for the third quarter of 2009 can be found on the "Investors" page at aflac.com, along with a complete listing of Aflac's investment holdings in the financial sector and a separate listing of the company's investments in perpetual securities.

Aflac Incorporated will webcast its third quarter conference call via the "Investors" page of aflac.com at 9:00 a.m. (EDT) on Thursday, October 29.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.